Bi-Specific Antibodies Therapy Industry Research Report 2024

Bi-Specific Antibodies Therapy Industry Research Report 2024


Summary

According to APO Research, The global Bi-Specific Antibodies Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

North American market for Bi-Specific Antibodies Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Bi-Specific Antibodies Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Bi-Specific Antibodies Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Bi-Specific Antibodies Therapy include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, AstraZeneca, AbbVie, Lindis Biotech and MacroGenics, Inc, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Bi-Specific Antibodies Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bi-Specific Antibodies Therapy.
The Bi-Specific Antibodies Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bi-Specific Antibodies Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Roche
Amgen
Sanofi
Pfizer
Johnson & Johnson
AstraZeneca
AbbVie
Lindis Biotech
MacroGenics, Inc
Genmab
Alphamab Co. Ltd
Akeso, Inc.
Bi-Specific Antibodies Therapy segment by Type

Fragment-Based Antibodies
IgG-Based Antibodies
Bi-Specific Antibodies Therapy segment by Application

Cancer
Haemophilia
Other Non-Cancer Diseases
Bi-Specific Antibodies Therapy Segment by Region

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bi-Specific Antibodies Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bi-Specific Antibodies Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bi-Specific Antibodies Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Bi-Specific Antibodies Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Bi-Specific Antibodies Therapy by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Fragment-Based Antibodies
2.2.3 IgG-Based Antibodies
2.3 Bi-Specific Antibodies Therapy by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 Cancer
2.3.3 Haemophilia
2.3.4 Other Non-Cancer Diseases
2.4 Assumptions and Limitations
3 Bi-Specific Antibodies Therapy Breakdown Data by Type
3.1 Global Bi-Specific Antibodies Therapy Historic Market Size by Type (2019-2024)
3.2 Global Bi-Specific Antibodies Therapy Forecasted Market Size by Type (2025-2030)
4 Bi-Specific Antibodies Therapy Breakdown Data by Application
4.1 Global Bi-Specific Antibodies Therapy Historic Market Size by Application (2019-2024)
4.2 Global Bi-Specific Antibodies Therapy Forecasted Market Size by Application (2019-2024)
5 Global Growth Trends
5.1 Global Bi-Specific Antibodies Therapy Market Perspective (2019-2030)
5.2 Global Bi-Specific Antibodies Therapy Growth Trends by Region
5.2.1 Global Bi-Specific Antibodies Therapy Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Bi-Specific Antibodies Therapy Historic Market Size by Region (2019-2024)
5.2.3 Bi-Specific Antibodies Therapy Forecasted Market Size by Region (2025-2030)
5.3 Bi-Specific Antibodies Therapy Market Dynamics
5.3.1 Bi-Specific Antibodies Therapy Industry Trends
5.3.2 Bi-Specific Antibodies Therapy Market Drivers
5.3.3 Bi-Specific Antibodies Therapy Market Challenges
5.3.4 Bi-Specific Antibodies Therapy Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Bi-Specific Antibodies Therapy Players by Revenue
6.1.1 Global Top Bi-Specific Antibodies Therapy Players by Revenue (2019-2024)
6.1.2 Global Bi-Specific Antibodies Therapy Revenue Market Share by Players (2019-2024)
6.2 Global Bi-Specific Antibodies Therapy Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Bi-Specific Antibodies Therapy Head office and Area Served
6.4 Global Bi-Specific Antibodies Therapy Players, Product Type & Application
6.5 Global Bi-Specific Antibodies Therapy Players, Date of Enter into This Industry
6.6 Global Bi-Specific Antibodies Therapy Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Bi-Specific Antibodies Therapy Market Size (2019-2030)
7.2 North America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Bi-Specific Antibodies Therapy Market Size by Country (2019-2024)
7.4 North America Bi-Specific Antibodies Therapy Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Bi-Specific Antibodies Therapy Market Size (2019-2030)
8.2 Europe Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Bi-Specific Antibodies Therapy Market Size by Country (2019-2024)
8.4 Europe Bi-Specific Antibodies Therapy Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Bi-Specific Antibodies Therapy Market Size (2019-2030)
9.2 Asia-Pacific Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country (2019-2024)
9.4 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 Latin America
10.1 Latin America Bi-Specific Antibodies Therapy Market Size (2019-2030)
10.2 Latin America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Bi-Specific Antibodies Therapy Market Size by Country (2019-2024)
10.4 Latin America Bi-Specific Antibodies Therapy Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Bi-Specific Antibodies Therapy Market Size (2019-2030)
11.2 Middle East & Africa Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2019-2024)
11.4 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 Players Profiled
12.1 Roche
12.1.1 Roche Company Information
12.1.2 Roche Business Overview
12.1.3 Roche Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)
12.1.4 Roche Bi-Specific Antibodies Therapy Product Portfolio
12.1.5 Roche Recent Developments
12.2 Amgen
12.2.1 Amgen Company Information
12.2.2 Amgen Business Overview
12.2.3 Amgen Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)
12.2.4 Amgen Bi-Specific Antibodies Therapy Product Portfolio
12.2.5 Amgen Recent Developments
12.3 Sanofi
12.3.1 Sanofi Company Information
12.3.2 Sanofi Business Overview
12.3.3 Sanofi Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)
12.3.4 Sanofi Bi-Specific Antibodies Therapy Product Portfolio
12.3.5 Sanofi Recent Developments
12.4 Pfizer
12.4.1 Pfizer Company Information
12.4.2 Pfizer Business Overview
12.4.3 Pfizer Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)
12.4.4 Pfizer Bi-Specific Antibodies Therapy Product Portfolio
12.4.5 Pfizer Recent Developments
12.5 Johnson & Johnson
12.5.1 Johnson & Johnson Company Information
12.5.2 Johnson & Johnson Business Overview
12.5.3 Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)
12.5.4 Johnson & Johnson Bi-Specific Antibodies Therapy Product Portfolio
12.5.5 Johnson & Johnson Recent Developments
12.6 AstraZeneca
12.6.1 AstraZeneca Company Information
12.6.2 AstraZeneca Business Overview
12.6.3 AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)
12.6.4 AstraZeneca Bi-Specific Antibodies Therapy Product Portfolio
12.6.5 AstraZeneca Recent Developments
12.7 AbbVie
12.7.1 AbbVie Company Information
12.7.2 AbbVie Business Overview
12.7.3 AbbVie Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)
12.7.4 AbbVie Bi-Specific Antibodies Therapy Product Portfolio
12.7.5 AbbVie Recent Developments
12.8 Lindis Biotech
12.8.1 Lindis Biotech Company Information
12.8.2 Lindis Biotech Business Overview
12.8.3 Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)
12.8.4 Lindis Biotech Bi-Specific Antibodies Therapy Product Portfolio
12.8.5 Lindis Biotech Recent Developments
12.9 MacroGenics, Inc
12.9.1 MacroGenics, Inc Company Information
12.9.2 MacroGenics, Inc Business Overview
12.9.3 MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)
12.9.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Product Portfolio
12.9.5 MacroGenics, Inc Recent Developments
12.10 Genmab
12.10.1 Genmab Company Information
12.10.2 Genmab Business Overview
12.10.3 Genmab Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)
12.10.4 Genmab Bi-Specific Antibodies Therapy Product Portfolio
12.10.5 Genmab Recent Developments
12.11 Alphamab Co. Ltd
12.11.1 Alphamab Co. Ltd Company Information
12.11.2 Alphamab Co. Ltd Business Overview
12.11.3 Alphamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)
12.11.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product Portfolio
12.11.5 Alphamab Co. Ltd Recent Developments
12.12 Akeso, Inc.
12.12.1 Akeso, Inc. Company Information
12.12.2 Akeso, Inc. Business Overview
12.12.3 Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2019-2024)
12.12.4 Akeso, Inc. Bi-Specific Antibodies Therapy Product Portfolio
12.12.5 Akeso, Inc. Recent Developments
13 Report Conclusion
14 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings